Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Sanuwave Health said today it entered a memorandum of understanding with eKare to develop novel wound care analysis and management solutions which integrates technology from both companies.
Through the deal, Sanuwave’s dermaPace wound treatment device will be linked with eKare’s inSight 3D wound imaging and analytics system to produce a comprehensive wound management solution, Suwanee, Ga.-based Sanuwave said. Read more
Surefire Medical touted data today from a retrospective analysis of 85 bridge-to-transplant liver cancer patients treated with transarterial chemoembolization.
The data showed that therapy delivered using the Surefire infusion system yielded an 80% complete response in 1 treatment compared to 52% with a standard endhole microcatheter. The analysis also demonstrated a lower recurrence rate of liver cancer at 1 month for patients that used Surefire’s technology instead of a conventional microcatheter. Read more
Ascensia Diabetes Care said today it inked a strategic alliance with Insulet to integrate connectivity between Insulet’s next-gen Omnipod system with Ascensia’s Contour Next One blood glucose monitoring system.
Through the deal, Parsippany, N.J.-based Ascensia’s Contour Next will be designed to pair via Bluetooth with the Omnipod Dash personal diabetes manager to automatically communicate blood glucose readings directly to the system. Readings provided will be used by Insulet’s Omnipod Dash PDM to calculate insulin dosing and support delivery of insulin. Read more
Novocure said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma.
In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients with bevacizumab-refractory recurrent GBM. Read more
A U.S. House panel yesterday advanced the Lower Chamber’s version of the bill to reauthorize the user fee deal between the medical device and drug industries and the FDA.
Medical device and drug companies pay user fees to have the FDA review their products. The last Medical Device User Fee Act in 2012 doubled user fees from $295 million over 5 years to $595 million, in exchange for performance goals set for the FDA. Read more